Donepezil Hydrochloride
Product Images NDC 0143-9747

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 0143-9747). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hikma Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Donepezil Hydrochloride Tablets 1)

Chemical structure of Donepezil Hydrochloride showing the arrangement of its aromatic rings, piperidine ring, and functional groups including methoxy and carbonyl groups, along with the associated hydrochloride molecule.*

FDA Label Image

Figure09 (Donepezil Hydrochloride Tablets 10)

A line graph depicting the mean change over six months from baseline in ADCS-ADL scores for patients on Donepezil 10 mg/day compared to placebo. The graph displays clinical improvement and decline on the vertical axis and months on the horizontal axis, showing Donepezil's effect versus placebo in a clinical study.*

FDA Label Image

Figure10 (Donepezil Hydrochloride Tablets 11)

A line graph depicting the cumulative percentage of patients completing 6 months of double-blind treatment with Donepezil Hydrochloride 10 mg/day versus placebo. The graph shows change from baseline on the horizontal axis and cumulative percentage of patients on the vertical axis, comparing ADCS-ADL-severe score changes over time.*

FDA Label Image

Donepezil Hydrochloride Tablets5 mg/30 Tablets (Donepezil Hydrochloride Tablets 12)

Donepezil Hydrochloride 5 mg tablets label from Hikma Pharmaceuticals USA Inc. The label indicates the product contains 30 tablets and is prescription only. It includes storage instructions to keep between 20°-25°C (68°-77°F), protected from light and moisture. The label also provides distributor information for West-ward Pharmaceutical Corp. in Eatontown, NJ and manufacturing details from Jordan.*

FDA Label Image

Donepezil Hydrochloride Tablets10 mg/30 Tablets (Donepezil Hydrochloride Tablets 13)

Donepezil Hydrochloride 10 mg tablets label showing 30 tablets per container. The label includes storage instructions, manufacturer Hikma Pharmaceuticals USA Inc., and distributor West-ward Pharmaceutical Corp. The NDC number 0143-9748-30 is visible along with a barcode and dosage form as tablets.*

FDA Label Image

Figure01 (Donepezil Hydrochloride Tablets 2)

A line graph illustrating the time-course change from baseline in ADAS-cog scores over 24 weeks for patients treated with Donepezil Hydrochloride at 5 mg/day and 10 mg/day versus placebo. The y-axis shows mean change with standard error, where negative values indicate clinical improvement and positive values indicate decline. The x-axis represents weeks of drug treatment. Data points show trends for clinical improvement with active treatment compared to decline with placebo.*

FDA Label Image

Figure02 (Donepezil Hydrochloride Tablets 3)

A cumulative percentage graph showing the change in ADAS-cog scores from baseline over 24 weeks of double-blind treatment with Donepezil Hydrochloride 5 mg and 10 mg daily, compared to placebo. The chart includes curves for placebo, 5 mg, and 10 mg dose groups, with a table summarizing percentage changes at various points.*

FDA Label Image

Figure03 (Donepezil Hydrochloride Tablets 4)

A bar chart showing the frequency distribution of CIBIC plus scores at Week 24 across three groups: Placebo, 5 mg/day, and 10 mg/day. The x-axis shows CIBIC plus ratings from Markedly Improved to Markedly Worse, while the y-axis represents the percentage of patients. Different bars compare the distribution for each treatment group.*

FDA Label Image

Figure04 (Donepezil Hydrochloride Tablets 5)

A line graph showing the mean change from baseline in ADAS-cog scores over 15 weeks of drug treatment and placebo for patients completing the study. The x-axis represents weeks of treatment, and the y-axis represents the change in ADAS-cog rating, with separate lines for placebo, 5 mg/day donepezil hydrochloride, and 10 mg/day donepezil hydrochloride. Clinical improvement and decline are indicated on the y-axis.*

FDA Label Image

Figure05 (Donepezil Hydrochloride Tablets 6)

A line graph showing the cumulative percentage of patients with specified changes from baseline ADAS-cog scores for Donepezil Hydrochloride 5 mg, 10 mg, and placebo groups. The x-axis represents change from baseline, the y-axis cumulative percentage of patients. A table within the graph displays changes in ADAS-cog scores for each treatment group.*

FDA Label Image

Figure06 (Donepezil Hydrochloride Tablets 7)

A bar graph showing the frequency distribution of CIBIC plus scores at week 12 across patients taking placebo, 5 mg/day, and 10 mg/day doses. The x-axis displays categories of patient change from markedly improved to markedly worse, and the y-axis shows the percentage of patients. Different bars represent placebo, 5 mg/day, and 10 mg/day groups.*

FDA Label Image

Figure07 (Donepezil Hydrochloride Tablets 8)

A line graph depicting the mean change from baseline in SIB (Severe Impairment Battery) score over 6 months for donepezil 10 mg/day versus placebo. The vertical axis shows clinical improvement or decline, while the horizontal axis shows time in months. Donepezil shows an increase in SIB score over time, whereas placebo shows a decrease.*

FDA Label Image

Figure08 (Donepezil Hydrochloride Tablets 9)

A cumulative percentage line graph comparing placebo and Donepezil 10 mg/day groups, showing change from baseline in SIB scores over 6 months of double-blind treatment. The x-axis represents change from baseline, and the y-axis shows cumulative percentage of patients completing the study.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.